At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGON CG Oncology Inc.
Trading 09-04 14:00:22 EDT
74.44
+0.11
+0.15%
High74.49Low72.87Vol114.43K
Open73.02D1 Closing74.33Amplitude2.18%
Mkt Cap6.60BTradable Cap4.82BTotal Shares88.64M
T/O8.46MT/O Rate0.18%Tradable Shares64.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CG Oncology CEO Joins Cantor Fitzgerald Global Healthcare Conference Fireside Chat
Reuters  ·  09-02 20:05
CG Oncology CEO Joins Cantor Fitzgerald Global Healthcare Conference Fireside Chat
CG Oncology to Present at Upcoming Investor Conferences in September
GlobeNewswire  ·  09-02 20:00
CG Oncology to Present at Upcoming Investor Conferences in September
UBS Keeps Their Buy Rating on CG Oncology, Inc. (CGON)
TIPRANKS  ·  08-20
UBS Keeps Their Buy Rating on CG Oncology, Inc. (CGON)
CG Oncology Director Leonard Post Disposes of USD 74,540 in Common Shares
Reuters  ·  08-19
CG Oncology Director Leonard Post Disposes of USD 74,540 in Common Shares
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CG Oncology, Inc. (CGON) and Zimmer Biomet Holdings (ZBH)
TIPRANKS  ·  08-13
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CG Oncology, Inc. (CGON) and Zimmer Biomet Holdings (ZBH)
CG Oncology Price Target Raised to $85.00/Share from $82.00 by Truist Securities
Dow Jones  ·  08-07
CG Oncology Price Target Raised to $85.00/Share from $82.00 by Truist Securities
RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating
MT Newswires Live  ·  08-07
RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating
Zentalis Q2 Net Loss Widens on Higher R&D Costs
Reuters  ·  08-07
Zentalis Q2 Net Loss Widens on Higher R&D Costs
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
TIPRANKS  ·  08-07
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
TriSalus Life Sciences Q2 Revenue Beats Estimates
Reuters  ·  08-07
TriSalus Life Sciences Q2 Revenue Beats Estimates
Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline
Reuters  ·  08-07
Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline
CG Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-06
CG Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
CG Oncology Publishes Investor Deck Highlighting Cretostimogene Data in High-Risk NMIBC Programs
Reuters  ·  08-06
CG Oncology Publishes Investor Deck Highlighting Cretostimogene Data in High-Risk NMIBC Programs
CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate
Benzinga Earnings  ·  08-06
CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate
CG Oncology Q2 Net Loss Widens on Higher R&D Costs
Reuters  ·  08-06
CG Oncology Q2 Net Loss Widens on Higher R&D Costs
Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.90 a Share, vs. FactSet Est of $0.66 Loss
MT Newswires Live  ·  08-06
Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.90 a Share, vs. FactSet Est of $0.66 Loss
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
THOMSON REUTERS  ·  08-06
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
CG Oncology Q2 EPS USD -0.9
THOMSON REUTERS  ·  08-06
CG Oncology Q2 EPS USD -0.9
CG Oncology Inc - Files for Offering of up to $500 Mln Common Stock - SEC Filing
THOMSON REUTERS  ·  08-06
CG Oncology Inc - Files for Offering of up to $500 Mln Common Stock - SEC Filing
Health Rounds: Experimental Cell Therapy Slows Heart Failure Progression in Duchenne Muscular Dystrophy
Reuters  ·  07-31
Health Rounds: Experimental Cell Therapy Slows Heart Failure Progression in Duchenne Muscular Dystrophy

Introduction

Company Name.
CG Oncology Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CG Oncology, Inc. was originally incorporated in California on September 24, 2010, and later reincorporated in Delaware on November 30, 2017. The company is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for the treatment of bladder cancer. Its clinical programs target patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer who have limited treatment options.
Issue price:
--